Suggested remit: To appraise the clinical and cost effectiveness of tirzepatide within its marketing authorisation for managing obesity or overweight with risk factors.
|
Status
|
In progress
|
|
Technology type
|
Medicine
|
|
Decision
|
Selected
|
|
Reason for decision
|
Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
|
| Process |
STA Standard
|
| ID number |
6179
|
Provisional Schedule
| Committee meeting: 1 |
16 January 2024 |
| Expected publication |
27 March 2024 |
Project Team
| Project lead |
Thomas Feist |
Email enquiries
| External Assessment Group |
Warwick Evidence, Warwick Medical School, University of Warwick |
Stakeholders
| Companies sponsors |
Eli Lilly and Company |
| Others |
Department of Health and Social Care |
| |
Health Technology Wales (HTW) |
| |
NHS England |
| |
Welsh Government |
| Patient carer groups |
All About Obesity |
| |
Diabetes UK |
| |
Obesity UK |
| Professional groups |
Association for the Study of Obesity |
| |
British Obesity and Metabolic Surgery Society |
| |
Royal College of General Practitioners |
| |
Royal College of Physicians |
| Comparator companies |
NovoNordisk |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
BNF |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
MHRA |
| |
Scottish Medicines Consortium |
| |
Welsh Health Specialised Services Committee |
|
Date
|
Update
|
|
13 June 2023
|
Invitation to participate |
|
26 May 2023
|
Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-June 2023. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission. |
|
23 March 2023
|
Following the changes to remove technical engagement as standard from appraisal timelines, the timelines for the appraisal of Tirzepatide for managing overweight and obesity have been revised. It is anticipated that the appraisal will begin in mid-May 2023 when we will write to you about how you can get involved. |
|
24 January 2023 - 21 February 2023
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
|
24 January 2023
|
In progress. Scoping commenced |
|
17 October 2022
|
Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual